Clinical Pharmacokinetics of Docetaxel

  title={Clinical Pharmacokinetics of Docetaxel},
  author={S. Clarke and L. Rivory},
  journal={Clinical Pharmacokinetics},
  • S. Clarke, L. Rivory
  • Published 1999
  • Medicine
  • Clinical Pharmacokinetics
  • Docetaxel (Taxotere®), a semi-synthetic analog of paclitaxel (Taxol®), is a promoter of microtubule polymerization leading to cell cycle arrest at G2/M, apoptosis and cytotoxicity. Docetaxel has significant activity in breast, non-small-cell lung, ovarian and head and neck cancers.Docetaxel has undergone phase I study in a number of schedules, including different infusion durations and various treatment cycles. Doses studied in adults have ranged from 5 to 145 mg/m2 and those in children from… CONTINUE READING
    255 Citations
    Clinical Pharmacokinetics of Docetaxel
    • 211
    Docetaxel: in gastric cancer.
    • 7
    Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients
    • 61
    The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel.
    • 98
    • PDF
    Docetaxel: an update of its use in advanced breast cancer.
    • 65
    A clinical pharmacokinetic microdosing study of docetaxel with Japanese patients with cancer
    • 8


    Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience.
    • 309
    • Highly Influential
    Preclinical evaluation of docetaxel (Taxotere).
    • 263
    • Highly Influential
    Preclinical pharmacokinetics of paclitaxel and docetaxel.
    • 131
    Preclinical pharmacology of docetaxel.
    • 74
    Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis.
    • 135
    Evaluation of the linearity of docetaxel pharmacokinetics
    • 38
    Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion.
    • 240
    • Highly Influential
    Early clinical studies with docetaxel
    • 25
    • Highly Influential
    Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors.
    • L. Pronk, J. Schellens, +10 authors J. Verweij
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 1997
    • 68
    Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.
    • C. Hudis, A. Seidman, +12 authors L. Norton
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 1996
    • 154